Science News: Safety and Efficacy of Eculizumab in Guillain-Barré Syndrome: A Multicentre, Double-blind, Randomised Phase 2 Trial 9/5/2018
Submitted by Leigh Maria K. Ramos-Platt, MD, News Science Editorial Board
Edited by Benn E. Smith, MD, News Science Editorial Board
Eculizumab is an anti-C5 humanized monoclonal antibody. Misawa et al report on a 34 patient, 24-week double-blind, randomized phase 2 study comparing IVIG and 4 weeks of eculizumab (900 mg per dose) versus IVIG and 4 weeks of placebo.